Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chromosomal translocations and sarcomas.

Jeannette L Bennicelli1, Frederic G Barr

  • 1Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA. jbennice@mail.med.upenn.edu

Current Opinion in Oncology
|July 20, 2002
PubMed
Summary

Identifying tumor-specific translocations and fusion proteins advances sarcoma understanding. This genetic insight impacts diagnosis, prognosis, and targeted therapies, offering new treatment avenues.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NAPRT expression and epigenetic regulation in pediatric rhabdomyosarcoma as a potential biomarker for NAMPT inhibition.

Molecular cancer therapeutics·2026
Same author

Biological Advances and Current Challenges for Pediatric Rhabdomyosarcoma.

Cancers·2026
Same author

Gene Amplification in Rhabdomyosarcoma: Lessons from a Rare Cancer.

International journal of molecular sciences·2026
Same author

MIR17HG Expression Is Transcriptionally Regulated by PAX3::FOXO1 and MYCN and is Necessary for Oncogenic Activity in Fusion-Positive Rhabdomyosarcoma.

bioRxiv : the preprint server for biology·2025
Same author

Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma.

Molecular cancer therapeutics·2025
Same author

Involvement of the FGF8/FGF Receptor Signaling Pathway in the Maintenance and Progression of Fusion-Positive Rhabdomyosarcoma.

Molecular cancer therapeutics·2025

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Sarcomas are a diverse group of cancers originating from connective tissues.
  • Tumor-specific genetic alterations, such as translocations and fusion proteins, are increasingly recognized as key drivers of sarcoma development.
  • Understanding these molecular underpinnings is crucial for improving patient outcomes.

Purpose of the Study:

  • To review the impact of identifying tumor-specific translocations and fusion proteins on sarcoma research and clinical practice.
  • To discuss how genetic discoveries are reshaping diagnostic and prognostic approaches.
  • To explore potential therapeutic strategies targeting sarcoma-specific molecular abnormalities.

Main Methods:

  • Review of recent scientific literature focusing on genetic alterations in various sarcoma subtypes.

Related Experiment Videos

  • Analysis of studies detailing specific fusion proteins (e.g., ASPL-TFE3, JAZF1-JJAZ1, HMGIC fusions).
  • Examination of research on the clinical implications of molecular genetic data, including diagnostics and prognostics.

    • Main Results:

    • Identification of key fusion proteins in alveolar soft part sarcoma, endometrial stromal sarcoma, and liposarcoma.
    • Demonstration of molecular genetic data influencing diagnostic accuracy and prognostic predictions.
    • Evidence of potential therapeutic applications, including targeted therapies like Gleevec and immunotherapy.

    Conclusions:

    • Tumor-specific translocations and fusion proteins are fundamental to understanding sarcoma biology.
    • Molecular genetic findings are revolutionizing sarcoma diagnosis, prognosis, and treatment strategies.
    • Targeting these specific genetic alterations holds significant promise for developing novel and effective sarcoma therapies.